Global efforts to end tuberculosis (TB) are still making progress, with fewer people falling ill and dying from the disease, according to a press release issued on 12 November 2026 by the World Health Organization (WHO). The findings come from the newly released WHO Global Tuberculosis Report 2026. Domestic funding for TB rose by 14% to US$ 5.6 billion between 2024 and 2025, partly offsetting a similar drop in international financing. The increase highlights the role of domestic investment in sustaining TB services during a global health funding crunch. Despite the gains, TB remains the leading cause of death from a single infectious agent.
In 2025, an estimated 10.6 million people developed TB and 1.1 million died from the disease. Deaths have fallen by 35% since 2015, and treatment has saved an estimated 86 million lives since 2000. With these results, the world has reached the first mortality milestone of WHO’s End TB Strategy, although five years later than planned. Since 2015, the global TB incidence rate has declined by 14%, far short of the 50% reduction milestone set for 2025. Progress has come too slowly against a preventable and treatable disease.
The global TB burden remains concentrated in 30 countries, which accounted for 88% of people who developed TB in 2025. Between 2015 and 2025, TB incidence fell by 42% in the WHO European Region and 30% in the African Region, compared with 18% in South-East Asia and only 6.6% in the Eastern Mediterranean. There was no net change in the Western Pacific. In the Americas, incidence rose for the fifth consecutive year in 2025, reaching 13% above 2015 levels. These differences reflect variations in TB risk factors, health system capacity, service access, and sustained investment.
Gaps in diagnosis and treatment remain significant. Of the 10.6 million people who developed TB in 2025, 8.4 million were diagnosed, leaving an estimated 2.2 million either undiagnosed or unreported. Only 59% of newly diagnosed patients were tested using a WHO-recommended rapid diagnostic test, well below the 100% target for 2027. Of the estimated 370 000 people with rifampicin-resistant TB in 2025, just 42% received treatment, although uptake of the six-month regimen rose from 18% in 2024 to 42% in 2025.
“The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
Research funding stood at US$ 1.2 billion in 2023, less than a quarter of the US$ 5 billion annual target for 2027. Greater investment is urgently needed to develop and roll out new vaccines, diagnostics, and treatments. WHO is calling on governments and partners to strengthen political commitment and protect sustainable financing for TB. The agency also urges rapid expansion of prevention, diagnosis, and treatment services, alongside accelerated investment in new tools. Faster progress is essential to put the world back on track toward ending the TB epidemic.